Teva Sees Continued Legal Overhang As Q3 Sales Miss Mark

Firm Expects Branded Drugs To Drive Revenues Going Forward

The company said it was optimistic about settling opioid litigation while still anticipating going to trial on price fixing.

Teva Pharmaceutical Industries Ltd. appears optimistic about settling opioid litigation as it continues to anticipate price-fixing litigation going to trial. But the company is anticipating a return to normal performance after the pandemic and sees two branded drugs launched in the last three years as well as generics as key drivers of growth.

[Sidebar#SC126163]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.